Phase 1 Open Label, Dose Escalation Trial of Intracoronary Infusion of AB-1002 in Subjects With NYHA Class III Heart Failure
Latest Information Update: 11 Apr 2025
At a glance
- Drugs AB 1002 (Primary)
- Indications Heart failure
- Focus First in man; Therapeutic Use
- Sponsors Asklepios BioPharmaceutical
Most Recent Events
- 08 Apr 2025 Planned End Date changed from 31 Aug 2028 to 30 Sep 2026.
- 08 Apr 2025 Status changed from recruiting to active, no longer recruiting.
- 12 Feb 2025 Planned number of patients changed from 12 to 17.